CPL409116 + methotrexate

**CPL409116 + methotrexate** is a combination investigational therapy being studied for the treatment of **active rheumatoid arthritis** in patients with an inadequate response to methotrexate alone. CPL409116 is a dual inhibitor of Janus kinase (JAK) and Rho-associated kinases (ROCK), developed by Celon Pharma. This mechanism is intended to reduce inflammation and modulate immune responses, which are key drivers in rheumatoid arthritis pathogenesis. The therapy is administered as an add-on to existing methotrexate treatment, which itself is a multifaceted immunosuppressive and antimetabolite agent targeting folate-dependent enzymes involved in nucleotide synthesis and lymphocyte proliferation. Methotrexate is a well-established **disease-modifying antirheumatic drug (DMARD)**, often used as the first-line agent for rheumatoid arthritis and other autoimmune inflammatory diseases. Its mechanism of action includes inhibition of dihydrofolate reductase, thymidylate synthase, and other folate metabolism enzymes, resulting in suppression of DNA synthesis and immunomodulation—primarily through increased adenosine signaling and reduced T-cell/B-cell activity[2][6][10]. CPL409116 aims to further suppress immune-mediated joint inflammation through potent dual inhibition of the JAK and ROCK signaling pathways, which are implicated in pro-inflammatory cytokine signaling and fibroblast activation, respectively.